Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectis S.A. stock logo
CLLS
Cellectis
$1.59
-3.9%
$1.49
$1.10
$2.43
$87.82M2.91143,539 shs37,406 shs
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$1.28
+1.6%
$1.24
$1.05
$9.21
$86.50M-0.13408,667 shs158,764 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.21
$3.27
$2.57
$6.88
$20.08M0.629,054 shs1,042 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.51
+2.7%
$1.48
$1.02
$7.89
$85.45M0.97407,966 shs185,958 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectis S.A. stock logo
CLLS
Cellectis
0.00%+9.31%+9.69%+37.83%-22.68%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
0.00%+8.47%+3.23%+9.40%+127,999,900.00%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-0.31%-5.89%-3.02%-42.27%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.00%+7.86%-10.12%+37.27%-74.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cellectis S.A. stock logo
CLLS
Cellectis
3.0595 of 5 stars
3.53.00.00.02.42.50.6
Climb Bio, Inc. stock logo
CLYM
Climb Bio
2.6322 of 5 stars
3.60.00.00.00.62.51.3
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.0175 of 5 stars
0.03.00.00.02.71.70.6
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
1.9804 of 5 stars
3.51.00.00.00.03.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$4.00152.37% Upside
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3.25
Buy$9.00603.13% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$7.80416.56% Upside

Current Analyst Ratings Breakdown

Latest NAII, CLYM, CLLS, and TCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$10.00
5/22/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/22/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$7.00
5/13/2025
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/7/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $10.00
5/6/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$7.00
4/8/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellectis S.A. stock logo
CLLS
Cellectis
$47.63M1.85N/AN/A$2.36 per share0.67
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/A$3.15 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.17N/AN/A$13.32 per share0.24
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$2.82M30.30N/AN/A$4.26 per share0.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellectis S.A. stock logo
CLLS
Cellectis
-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$73.90M-$2.38N/AN/AN/AN/A-43.95%-42.94%8/13/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$127.50M-$1.09N/AN/AN/A-2,974.08%-55.76%-36.56%8/11/2025 (Estimated)

Latest NAII, CLYM, CLLS, and TCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$0.15-$0.31-$0.16-$0.31N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/12/2025Q1 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million
5/12/2025Q1 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellectis S.A. stock logo
CLLS
Cellectis
0.44
1.67
1.67
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/A
14.25
14.25
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.15
8.55
8.55

Institutional Ownership

CompanyInstitutional Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
69.76%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%

Insider Ownership

CompanyInsider Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
0.80%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
4.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable
Climb Bio, Inc. stock logo
CLYM
Climb Bio
967.58 million67.04 millionN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10056.59 million54.13 millionNot Optionable

Recent News About These Companies

Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)
TScan Therapeutics appoints Camiolo as SVP, Market Access
TScan Therapeutics assumed with an Overweight at Morgan Stanley
TScan Therapeutics price target lowered to $3 from $14 at Barclays

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.58 -0.07 (-3.94%)
As of 07/3/2025 03:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Climb Bio stock logo

Climb Bio NASDAQ:CLYM

$1.28 +0.02 (+1.59%)
As of 07/3/2025 01:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.21 0.00 (0.00%)
As of 07/3/2025 02:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.51 +0.04 (+2.72%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$1.51 0.00 (0.00%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.